Data about who is affected by sesame allergy, the ninth allergen in the United States, were released in an effort to convince the FDA to label it as a major food allergen.
Using a survey of nearly 52,000 households across the United States, researchers found an increasing prevalence of sesame allergy, making it the ninth most common allergy in the United States. The findings were presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology in San Francisco, California Saturday.
The survey collected responses for 78,853 US children and adults, finding that 0.2% of individuals in the United States are allergic to sesame, which approaches the prevalence rates of other allergens such as soy and pistachio. The data, as well as other results from previously released findings from this data set, are being used in an effort to convince the FDA to add sesame to the list of other “top 8” allergens that must appear on manufactured food packages.
By age, the highest prevalence rates were observed among young adults aged 18 to 29 (0.33%), while the lowest rates were seen among adults 60 or older (0.09%).
On Saturday, researchers gave additional details about sesame allergy:
The survey was completed in 2015 and 2016.
Because sesame is not listed as a major food allergen, those with the allergy are vulnerable to accidental exposure, which can turn into anaphylaxis. Labeling is inconsistent in the United States—a few companies voluntarily label for sesame, but not all. However, the seed is labeled on packages in Canada, Australia, New Zealand, and the European Union.
In the United States, federal law was changed in 2004 to require that manufacturers label food for the 8 major allergens that cause most reactions: milk, eggs, fish, crustacean shellfish, tree nuts, wheat, peanuts, and soybeans.
Last October the FDA put out a request for comments about adding sesame to that list and so far has received 4821, which are overwhelmingly in favor of making the change.
In 2014, the Center for Science in the Public Interest (CSPI) asked the FDA to add sesame. The sesame research from Northwestern University is aimed at helping that effort. In a comment posted to the FDA, CSPI said a further request for information by the FDA is “itself unnecessary as a first step toward sesame labeling, insofar as it may delay more decisive action by the agency.”
“With evidence mounting that sesame allergy is on the rise, and can result in severe reactions, we are hopeful that the Food and Drug Administration will take these data into account as they determine whether or not to add sesame to their list of major food allergens,” Ruchi S. Gupta, MD, MPH, said in a statement. Gupta is a professor of Pediatrics and Medicine, Northwestern University, and director of the Science and Outcomes of Allergy and Asthma Research Program.
Earlier this week, an FDA spokeswoman said in an email to The American Journal of Managed Care® that it does not comment about the timing of future actions and it is “currently reviewing the comments submitted to the docket to help inform us of next steps.”
Reference
Chadha AS, Doshi P, Warren CM, et al. Epidemiology of sesame allergy in the United States. Presented at: American Academy of Allergy, Asthma & Immunology 2019 Annual Meeting; February 22-25, 2019; San Francisco, CA. Abstract 615.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
Early Intervention, Targeted Strategies Needed to Improve Disparities, Survival in Patients With IPF
October 17th 2024Two posters presented at the CHEST 2024 annual meeting highlighted the importance of addressing socioeconomic disparities and identifying clinical predictors to improve outcomes and survival rates among patients with idiopathic pulmonary fibrosis (IPF).
Read More